These include antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death checkpoint-1 (PD-1), and programmed death ligand-1 (PD-L1) to block immune regulatory checkpoints on tumor cells, immune cells, fibroblasts, and endothelial cells (17). The gene discussed is CD274; the disease is neoplasm.